Novel NO-TZDs and trimethoxychalcone-based DHPMs: design, synthesis, and biological evaluation as potential VEGFR-2 inhibitors
- PMID: 38904116
- DOI: 10.1080/14756366.2024.2358934
Novel NO-TZDs and trimethoxychalcone-based DHPMs: design, synthesis, and biological evaluation as potential VEGFR-2 inhibitors
Abstract
Novel series of nitric oxide-releasing thiazolidine-2,4-diones (NO-TZD-3a-d,5,6) and 3,4,5-trimethoxychalcone-based multifunctional 1,4-dihydropyrimidines (CDHPM-10a-g) have been designed and synthesised as potent broad-spectrum anticancer agents with potential VEGFR-2 inhibition. The designed analogs were evaluated for their anticancer activities towards a full panel of NCI-60 tumour cell lines and CDHPM-10a-g emerged mean %inhibitions ranging from 76.40 to 147.69%. Among them, CDHPM-10e and CDHPM-10f demonstrated the highest MGI% of 147.69 and 140.24%, respectively. Compounds CDHPM-10a,b,d-f showed higher mean %inhibitory activity than the reference drug sorafenib (MGI% = 105.46%). Superiorly, the hybrid CDHPM-10e displayed the highest potencies towards all the herein tested subpanels of nine types of cancer with MGI50 of 1.83 µM. Also, it revealed potent cytostatic single-digit micromolar activity towards the herein examined cancer cell lines. The designed compounds CDHPM-10a-g were exposed as potent non-selective broad-spectrum anticancer agents over all NCI subpanels with an SI range of 0.66-1.97. In addition, the target analog CDHPM-10e revealed potency towards VEGFR-2 kinase comparable to that of sorafenib with a sub-micromolar IC50 value of 0.11 µM. Also, CDHPM-10e could effectively induce Sub-G1-phase arrest and prompt apoptosis via caspase and p53-dependent mechanisms. Furthermore, CDHPM-10e revealed significant anti-metastatic activity as detected by wound healing assay. The modelling study implies that CDHPM-10e overlaid well with sorafenib and formed a strong H-bond in the DFG binding domain. The ADMET studies hinted out that CDHPM-10e met Pfizer's drug-likeness criteria. The presented novel potent anticancer agent merits further devotion as a new lead product in developing more chalcone-based VEGFR-2 inhibitors.
Keywords: 1,4-dihydropyrimidine; 3,4,5-trimethoxychalcone; NO-TZD; OpenEye; five-dose.
Similar articles
-
Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.Bioorg Med Chem Lett. 2022 Feb 15;58:128529. doi: 10.1016/j.bmcl.2022.128529. Epub 2022 Jan 7. Bioorg Med Chem Lett. 2022. PMID: 35007724 Review.
-
Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.Bioorg Chem. 2021 Mar;108:104669. doi: 10.1016/j.bioorg.2021.104669. Epub 2021 Jan 21. Bioorg Chem. 2021. PMID: 33515863
-
Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation.J Enzyme Inhib Med Chem. 2021 Dec;36(1):307-318. doi: 10.1080/14756366.2020.1861606. J Enzyme Inhib Med Chem. 2021. PMID: 33349069 Free PMC article.
-
Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.Arch Pharm (Weinheim). 2021 Feb;354(2):e2000279. doi: 10.1002/ardp.202000279. Epub 2020 Oct 19. Arch Pharm (Weinheim). 2021. PMID: 33073374
-
Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.Anticancer Agents Med Chem. 2018;18(8):1184-1196. doi: 10.2174/1871520618666180412123833. Anticancer Agents Med Chem. 2018. PMID: 29651967
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
